{"groups":[{"description":"Participants with deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration- sensitive prostate cancer (mCSPC) were randomized to receive placebo matching to niraparib and abiraterone acetate (AA) fixed dose combination (FDC) tablets along with AA tablets (4\\*250 mg tablet) and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"FG000","title":"Placebo With Abiraterone Acetate Plus Prednisone"},{"description":"Participants with deleterious germline or somatic HRR gene-mutated mCSPC were randomized to receive niraparib and AA FDC tablets (2\\* \\[100 mg niraparib/500 mg AA tablet\\]) along with placebo matching to AA tablet and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"FG001","title":"Niraparib With Abiraterone Acetate Plus Prednisone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"249"}],"type":"Ongoing"},{"reasons":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"84"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Regional Crisis"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"348"},{"groupId":"FG001","numSubjects":"348"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"348"},{"groupId":"FG001","numSubjects":"347"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"196"},{"groupId":"FG001","numSubjects":"191"}],"type":"BRCA Subgroup"},{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"230"}],"type":"HRR Effector Subgroup"},{"achievements":[{"groupId":"FG000","numSubjects":"348"},{"groupId":"FG001","numSubjects":"348"}],"type":"All HRR"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"348"},{"groupId":"FG001","numSubjects":"348"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The results presented are based on the primary completion date (07 January 2025). Remaining results will be reported within a year of study completion."}